Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (20): 3715-3719.doi: 10.3969/j.issn.1673-8225.2012.20.024

Previous Articles     Next Articles

Essential role of microRNA-146a in proliferation and apoptosis of vascular smooth muscle cells 

Xiong Wei1, Dong Shao-hong1, Yuan Jian-hui2, Liu Jian-jun2, Xu Xin-yun2, Li Jiang-hua1   

  1. 1Department of Cardiology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen  518020, Guangdong Province, China; 2Key Laboratory of Modern Toxicology in Shenzhen, Shenzhen Center for Disease Control and Prevention, Shenzhen  518020, Guangdong Province, China
  • Received:2012-03-01 Revised:2012-03-19 Online:2012-05-13 Published:2012-05-13
  • Contact: Dong Shao-hong, Doctor, Professor, Department of Cardiology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China dsh266@medmail.com.cn
  • About author:Xiong Wei☆, Studying for doctorate, Attending physician, Department of Cardiology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China xw1012@sina.com
  • Supported by:

     the Science and Technology Plan of Shenzhen City, No. 201102158*

PDF

454

Abstract:

BACKGROUND: MicroRNA-146a (miRNA-146a) can mediate the proliferation of immune cells and tumor cells through negative regulation of nuclear factor κB signaling pathway, but whether miRNA-146a participates in the proliferation or apoptosis of vascular smooth muscle cells (VSMCs) has not been reported.
OBJECTIVE: To investigate the role of miRNA-146a in VSMCs proliferation and apoptosis and to exploit its mechanisms.
METHODS: Artificial synthesized miRNA-146a antisense oligonucleotide (ASO, 50 nmol/L), scramble (control, 50nmol/l) and phosphate buffered saline (normal) were transfected into VSMCs by Lipofectamine 2000 individually.
RESULTS AND CONCLUSION: By the end of 48 hours of transfection, there were significantly lower levels of miRNA-146a mRNA in ASO treated VSMCs compared with that in normal and control VSMCs (P < 0.01). Meanwhile, ASO treated VSMCs manifested a lower proliferative (P < 0.01) and higher apoptotic ability (P < 0.05). The protein level of nuclear factor-κBp65 and proliferation cell nuclear antigen in ASO treated VSMCs were remarkably lower than that in normal and control VSMCs (P < 0.05). miRNA-146a is capable of promoting proliferation and suppressing apoptosis of VMSCs, which is probably related with the increase in nuclear factor-κBp65 expression.

CLC Number: